Xylazine in Turkey: not individually verified
We have not confirmed that Xylazine specifically is scheduled in Turkey, so this page gives no legal status. Publishing a guess here would be worse than publishing nothing. What we do know is the governing national drug law, below.
- What is on record
- Not confirmed. Xylazine is not confirmed as a controlled substance in Turkey and this row is a deferral rather than a finding. The dossier searched the Turkish term «ksilazin» and the transliteration ksilazin against the classification decisions made under article 19 of Law No. 2313 on the Control of Narcotic Substances, and confirmed no current entry. It rejected the near match «ketamin», because the veterinary sedative is chemically different, and that rejection is a good one: xylazine is an alpha-2 adrenergic agonist and not a dissociative anaesthetic, and it is associated with ketamine only because the two are used together in animal practice. Article 19 reaches poisons shown by scientific examination to be harmful and to produce toxicomania; whether xylazine has been brought under it was not established. Veterinary medicines law may govern it and was not read.
Confirm directly with Turkey’s national drug authority or your own embassy before you rely on anything.
This page is deliberately excluded from search indexing and from our sitemap. Only confirmed, individually verified statuses are published as indexable pages.
Before you travel
Verify current rules with the destination country’s official drug authority and your own country’s embassy before traveling. Find the destination’s U.S. embassy & official country guidance →
Non-U.S. travelers: check your own government’s travel advisory and embassy.
If you’re detained or arrested abroad
Contact your own country’s embassy or consulate in the destination immediately, not the destination’s authorities. U.S. citizens: contact the nearest U.S. embassy/consulate and the U.S. State Department at +1-202-501-4444 (from abroad). If a U.S. citizen is arrested or detained abroad →
